Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 18;22(6):3092.
doi: 10.3390/ijms22063092.

Nanomaterials for the Diagnosis and Treatment of Inflammatory Arthritis

Seyedeh Maryam Hosseinikhah  1 , Mahmood Barani  2 , Abbas Rahdar  3 , Henning Madry  4 , Rabia Arshad  5 , Vahideh Mohammadzadeh  6 , Magali Cucchiarini  4
Affiliations
Review

Nanomaterials for the Diagnosis and Treatment of Inflammatory Arthritis

Seyedeh Maryam Hosseinikhah et al. Int J Mol Sci. .

Erratum in

Abstract

Nanomaterials have received increasing attention due to their unique chemical and physical properties for the treatment of rheumatoid arthritis (RA), the most common complex multifactorial joint-associated autoimmune inflammatory disorder. RA is characterized by an inflammation of the synovium with increased production of proinflammatory cytokines (IL-1, IL-6, IL-8, and IL-10) and by the destruction of the articular cartilage and bone, and it is associated with the development of cardiovascular disorders such as heart attack and stroke. While a number of imaging tools allow for the monitoring and diagnosis of inflammatory arthritis, and despite ongoing work to enhance their sensitivity and precision, the proper assessment of RA remains difficult particularly in the early stages of the disease. Our goal here is to describe the benefits of applying various nanomaterials as next-generation RA imaging and detection tools using contrast agents and nanosensors and as improved drug delivery systems for the effective treatment of the disease.

Keywords: inflammatory arthritis; nanodiagnosis; nanotreatments.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Different nanoparticles (NPs) for imaging and biosensing of inflammatory arthritis.
Figure 2
Figure 2
Liposomes as nanocarriers for the delivery of drugs in the treatment of RA.
Figure 3
Figure 3
CS-siRNA NP delivery in macrophages to suppress TNF-α expression. Macrophage elimination by CS-siRNA NPs was established to inhibit a local production of IL-1β, IL-6, TNF-α, and matrix metalloproteinases (MMPs) and thus reduce the pathogenesis of inflammatory arthritis.
Figure 4
Figure 4
Structure of niosomes for the transfer of various drugs to target locations.
See this image and copyright information in PMC

References

    1. Rosenzwajg M., Lorenzon R., Cacoub P., Pham H.P., Pitoiset F., El Soufi K., RIbet C., Bernard C., Aractingi S., Banneville B. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann. Rheum. Dis. 2019;78:209–217. doi: 10.1136/annrheumdis-2018-214229. - DOI - PubMed
    1. Molano-González N., Rojas M., Monsalve D.M., Pacheco Y., Acosta-Ampudia Y., Rodríguez Y., Rodríguez-Jimenez M., Ramírez-Santana C., Anaya J.-M. Cluster analysis of autoimmune rheumatic diseases based on autoantibodies. New insights for polyautoimmunity. J. Autoimmun. 2019;98:24–32. doi: 10.1016/j.jaut.2018.11.002. - DOI - PubMed
    1. Blum A., Adawi M. Rheumatoid arthritis (RA) and cardiovascular disease. Autoimmun. Rev. 2019;18:679–690. doi: 10.1016/j.autrev.2019.05.005. - DOI - PubMed
    1. Sima C., Viniegra A., Glogauer M. Macrophage immunomodulation in chronic osteolytic diseases—The case of periodontitis. J. Leukoc. Biol. 2019;105:473–487. doi: 10.1002/JLB.1RU0818-310R. - DOI - PMC - PubMed
    1. Saper V.E., Chen G., Deutsch G.H., Guillerman R.P., Birgmeier J., Jagadeesh K., Canna S., Schulert G., Deterding R., Xu J. Emergent high fatality lung disease in systemic juvenile arthritis. Ann. Rheum. Dis. 2019;78:1722–1731. doi: 10.1136/annrheumdis-2019-216040. - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources